ArticleClinical transplantation and research2025
Status quo of histocompatibility testing and prospects for virtual crossmatching within the Korean kidney allocation system: survey of laboratory directors.
Article in Clinical transplantation and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- IgG Subclass Profiles of HLA Antibodies Enhance Prediction of C1q-Binding in Kidney Transplant Recipients.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Korean kidney allocation system (KAS) currently imposes disparities for highly sensitized candidates because it does not account for human leukocyte antigen (HLA) antibody-defined unacceptable antigens. Virtual crossmatch (VXM) may provide a solution by enhancing histocompatibility assessment and improving the efficiency of the overall allocation process. This study surveyed Korean HLA laboratory directors to evaluate current practices, opinions on VXM, and prerequisites for its implementation. Methods: An electronic survey addressing HLA typing, HLA antibody testing, and VXM concepts was distributed to 48 histocompatibility laboratory directors in September 2024. Responses were received from 31 institutions (64.6% response rate), representing 72.9% of deceased donor kidney transplants performed in Korea in 2024. Results: All responding institutions conducted HLA typing and physical crossmatch (PXM). Only 61.3% performed single antigen bead assays in-house, and 77.4% reported donor HLA typing at the two-digit serological level. A strong consensus (88.9%) defined highly sensitized candidates as those with calculated panel-reactive antibody >80%, with 66.7% supporting their prioritization. All participants (100%) recognized "improved process efficiency by excluding highly sensitized patients with presumed PXM positivity from the allocation process" (44.3%) as the greatest benefit of implementing VXM, although mean fluorescence intensity cutoffs and testing intervals varied by institution. Conclusions: Korean HLA laboratory directors broadly support the concept and need for VXM, acknowledging its potential to improve both efficiency and equity for sensitized patients. However, the lack of standardization in HLA testing application and interpretation remains a significant practical challenge. National initiatives and multidisciplinary collaboration are essential before integrating VXM into the Korean KAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.